

Carlos Guijarro Herraiz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1501057/publications.pdf>

Version: 2024-02-01

108
papers

5,317
citations

159358

30
h-index

88477

70
g-index

143
all docs

143
docs citations

143
times ranked

9401
citing authors

#	ARTICLE	IF	CITATIONS
1	Repurposed Antiviral Drugs for Covid-19 " Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021, 384, 497-511.	13.9	2,014
2	Transcription factor- $\hat{\rho}$ B (NF- $\hat{\rho}$ B) and renal disease. <i>Kidney International</i> , 2001, 59, 415-424.	2.6	443
3	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture. <i>Circulation Research</i> , 1998, 83, 490-500.	2.0	379
4	Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. <i>Kidney International</i> , 1996, 49, 518-524.	2.6	283
5	Mortality among adult patients admitted to the hospital on weekends. <i>European Journal of Internal Medicine</i> , 2006, 17, 322-324.	1.0	111
6	Effect of Simultaneous Use of Highly Active Antiretroviral Therapy on Survival of HIV Patients With Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 148-152.	0.9	105
7	Early glomerular changes in rats with dietary-induced hypercholesterolemia. <i>American Journal of Kidney Diseases</i> , 1995, 26, 152-161.	2.1	82
8	Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. <i>American Journal of Kidney Diseases</i> , 1998, 31, 190-194.	2.1	77
9	Low-Density Lipoprotein-Induced Expression of Interleukin-6, a Marker of Human Mesangial Cell Inflammation: Effects of Oxidation and Modulation by Lovastatin. <i>Biochemical and Biophysical Research Communications</i> , 2000, 267, 536-540.	1.0	69
10	Serum albumin and mortality after renal transplantation. <i>American Journal of Kidney Diseases</i> , 1996, 27, 117-123.	2.1	67
11	Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. <i>Kidney International</i> , 1995, 48, 363-371.	2.6	66
12	Cardiovascular disease after renal transplantation. <i>Kidney International</i> , 2002, 61, S78-S84.	2.6	62
13	Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. <i>Lung</i> , 2021, 199, 249-253.	1.4	56
14	Neoplasms of Unknown Primary Site: A Clinicopathological Study of Autopsied Patients. <i>Tumori</i> , 1993, 79, 321-324.	0.6	51
15	The central role of nuclear factor- $\hat{\rho}$ B in mesangial cell activation. <i>Kidney International</i> , 1999, 56, S76-S79.	2.6	51
16	Fatigue and Dyspnoea as Main Persistent Post-COVID-19 Symptoms in Previously Hospitalized Patients: Related Functional Limitations and Disability. <i>Respiration</i> , 2022, 101, 132-141.	1.2	50
17	Expression of leucocyte chemoattractants by interstitial renal fibroblasts: up-regulation by drugs associated with interstitial fibrosis. <i>Clinical and Experimental Immunology</i> , 1996, 106, 518-522.	1.1	47
18	Statins: effects beyond cholesterol lowering. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1738-1741.	0.4	45

#	ARTICLE	IF	CITATIONS
19	Elevated Liver Enzymes Following Initiation of Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2000, 283, 2526-2527.	3.8	44
20	Assessing clinical probability of organic disease in patients with involuntary weight loss: a simple score. European Journal of Internal Medicine, 2002, 13, 240-245.	1.0	40
21	Anxiety, depression and poor sleep quality as long-term post-COVID sequelae in previously hospitalized patients: A multicenter study. Journal of Infection, 2021, 83, 496-522.	1.7	40
22	Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The LONG-COVID-EXP-CM Multicenter Study. International Journal of Infectious Diseases, 2022, 116, 241-244.	1.5	38
23	Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney International, 1999, 56, S88-S91.	2.6	37
24	Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. Journal of Infection, 2021, 83, 237-279.	1.7	37
25	Diabetes and the Risk of Long-term Post-COVID Symptoms. Diabetes, 2021, 70, 2917-2921.	0.3	37
26	Lipid-Induced Glomerular Injury. Nephron, 1994, 67, 1-6.	0.9	35
27	Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain. Advances in Therapy, 2015, 32, 944-961.	1.3	35
28	Lovastatin inhibits lipopolysaccharide-induced NF- κ B activation in human mesangial cells. Nephrology Dialysis Transplantation, 1996, 11, 990-996.	0.4	31
29	Lipoprotein changes in patients with chronic hepatitis C treated with interferon- α . American Journal of Gastroenterology, 1998, 93, 1901-1904.	0.2	30
30	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. Atherosclerosis, 2019, 287, 89-92.	0.4	29
31	Indicaciones de los inhibidores de PCSK9 en la prÁctica clÁnica. Recomendaciones de la Sociedad Espa±ola de Arteriosclerosis (SEA), 2019. ClÁnica E Investigaci³n En Arteriosclerosis, 2019, 31, 128-139.	0.4	28
32	How primordial magnetic fields shrink galaxies. Monthly Notices of the Royal Astronomical Society, 2020, 495, 4475-4495.	1.6	24
33	Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital. Enfermedades Infecciosas Y MicrobiologÁa ClÁnica, 2022, 40, 302-309.	0.3	24
34	Increased Lipoproteins and Fibrinogen in Chronic Renal Allograft Dysfunction. American Journal of Nephrology, 1997, 17, 445-449.	1.4	22
35	Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain. DYSIS-Spain Study. Revista Espanola De Cardiologia (English Ed), 2011, 64, 286-294.	0.4	22
36	A simple prognostic score for risk assessment in patients with acute pancreatitis. European Journal of Internal Medicine, 2009, 20, e43-e48.	1.0	21

#	ARTICLE	IF	CITATIONS
37	Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Archives of Internal Medicine, 1997, 157, 227-232.	4.3	21
38	Lipid abnormalities in stable liver transplant recipients - effects of cyclosporin, tacrolimus, and steroids. Transplant International, 1998, 11, 137-142.	0.8	20
39	IMMUNOSUPPRESSIVE EFFECTS OF LEFLUNOMIDE IN EXPERIMENTAL CHRONIC VASCULAR REJECTION. Transplantation, 1995, 60, 887-890.	0.5	20
40	Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Current Opinion in Nephrology and Hypertension, 1993, 2, 372-379.	1.0	14
41	Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. Kidney International, 1999, 56, S80-S83.	2.6	14
42	Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. Open Forum Infectious Diseases, 2021, 8, ofab299.	0.4	14
43	Similar prevalence of long-term post-COVID symptoms in patients with asthma: A case-control study. Journal of Infection, 2021, 83, 237-279.	1.7	14
44	Occult Vascular Lesions in Patients with Atherothrombotic Events: The AIRVAG Cohort. European Journal of Vascular and Endovascular Surgery, 2005, 30, 57-62.	0.8	13
45	Colesterol LDL y aterosclerosis: evidencias. Clínica E Investigaci3n En Arteriosclerosis, 2021, 33, 25-32.	0.4	13
46	High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. Circulation, 2001, 104, .	1.6	12
47	Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults. Journal of Clinical Gastroenterology, 2019, 53, 717-723.	1.1	12
48	Peripheral Arterial Disease Is a Marker of Risk for Abdominal Aortic Aneurysms in Patients With Coronary Artery Disease. American Journal of Cardiology, 2006, 97, 1549-1550.	0.7	11
49	Visceral leishmaniasis in HIV-infected patients. Aids, 1991, 5, 1272-1273.	1.0	10
50	Central Role of the Transcription Factor Nuclear Factor- κ B in Mesangial Cell Production of Chemokines. , 1997, 120, 210-218.		10
51	Secondary Prevention of Arterial Disease in Very Elderly People: Results From a Prospective Registry (FRENA). Angiology, 2008, 59, 427-434.	0.8	10
52	SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study. Clinical Microbiology and Infection, 2021, 27, 1699.e1-1699.e4.	2.8	10
53	Differences in the use of health resources by Spanish and immigrant HIV-infected patients. Enfermedades Infecciosas Y Microbiolog3a Cl3nica, 2012, 30, 458-462.	0.3	9
54	Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma. Acta Haematologica, 2022, 145, 384-393.	0.7	9

#	ARTICLE	IF	CITATIONS
55	Spontaneous Bacterial Peritonitis Due to <i>Yersinia enterocolitica</i> in Secondary Alcoholic Hemochromatosis. <i>Journal of Clinical Gastroenterology</i> , 1989, 11, 675-678.	1.1	8
56	Decisiones al final de la vida: suspensión de antibióticos en presencia de infección activa. <i>Revista Española De Geriatria Y Gerontología</i> , 2006, 41, 297-300.	0.2	8
57	Estándares SEA 2019 para el control global del riesgo cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 1-43.	0.4	8
58	Lipoprotein changes in patients with chronic hepatitis C treated with interferon- α . <i>American Journal of Gastroenterology</i> , 1998, 93, 1901-1904.	0.2	7
59	Severe Polycythemia as the First Clinical Presentation of Hepatopulmonary Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 89-91.	1.1	7
60	Regulation of Mesangial Cell Proliferation by the Mevalonate Pathway. , 1997, 120, 191-196.		6
61	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2019, 31, 128-139.	0.1	6
62	Acute encephalopathy in adult as delayed presentation of occupational lead intoxication.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 127-128.	0.9	5
63	Inhibidores de PCSK9: ratificación del papel del colesterol LDL en prevención cardiovascular. ¿Hacia la convergencia en las guías de prevención europeas y norteamericanas?. <i>Revista Clínica Española</i> , 2020, 220, 374-382.	0.2	5
64	EFFECT OF FENOFIBRATES IN HEART TRANSPLANT PATIENTS. <i>Transplantation</i> , 1995, 59, 451.	0.5	4
65	Lipids and Progressive Renal Failure. <i>Contributions To Nephrology</i> , 1996, 118, 17-23.	1.1	4
66	Device Closure for Stroke with Patent Foramen Ovale. <i>New England Journal of Medicine</i> , 2012, 366, 2322-2324.	13.9	4
67	Effects on intestinal microbiota of probiotic fermented milk used for prevention of antibiotic-associated diarrhoea. <i>European Food Research and Technology</i> , 2012, 235, 1199-1206.	1.6	4
68	Recomendaciones de la guía para el diagnóstico y tratamiento del aneurisma de aorta abdominal. <i>Angiología</i> , 2015, 67, 297-303.	0.0	4
69	PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity. <i>JAMA Cardiology</i> , 2017, 2, 1168.	3.0	4
70	Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis. <i>Rheumatology International</i> , 2020, 40, 969-981.	1.5	4
71	Perfil clínico de los pacientes tratados con evolocumab en unidades de Lipidos/medicina interna en España. Estudio observacional (RETOSS-IMU). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 183-192.	0.4	4
72	Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology. <i>REC: CardioClinics</i> , 2021, 56, 208-217.	0.1	4

#	ARTICLE	IF	CITATIONS
73	Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. Revista Clínica Española, 2022, 222, 82-90.	0.3	4
74	Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional. Clínica e Investigación en Arteriosclerosis, 2022, 34, 10-18.	0.4	4
75	Recomendaciones para mejorar el control lipídico en pacientes en prevención primaria. Documento de consenso de la Sociedad Española de Cardiología. REC: CardioClinics, 2021, 56, 118-128.	0.1	3
76	SARS-CoV-2 reinfection in a closed setting: lessons for the community. Lancet Respiratory Medicine, 2021, 9, 675-677.	5.2	3
77	Exploring the recovery curve for gastrointestinal symptoms from the acute COVID-19 phase to long-term post-COVID: The LONG-COVID-EXPEM Multicenter Study. Journal of Medical Virology, 2022, 94, 2925-2927.	4.5	3
78	Sustained low-density lipoprotein cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting. European Journal of Clinical Investigation, 2022, 52, e13732.	1.7	3
79	Expenditures for the Care of Patients with HIV. New England Journal of Medicine, 2001, 344, 1948-1949.	13.9	2
80	In search of lost time: age, CVD, and intensive statin treatment. Lancet, 2008, 372, 535.	6.3	2
81	Thyroid Hormone Resistance and Pituitary Enlargement After Thyroid Ablation in a Woman on Levothyroxine Treatment. Thyroid, 2008, 18, 1119-1123.	2.4	2
82	Enfermedad arterial oclusiva en los estudios REACH, FRENA y AIRVAG. Annals of Vascular Surgery, 2009, 23, 21-27.	0.0	2
83	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. JAMA Cardiology, 2020, 5, 1452.	3.0	2
84	Evaluating the efficacy of an Advanced Care Planning Program for Health Decisions in patients with advanced heart failure: protocol for a Randomized Clinical Trial. BMC Cardiovascular Disorders, 2020, 20, 456.	0.7	2
85	COVID-19 y enfermedad cardiovascular. Clínica e Investigación en Arteriosclerosis, 2020, 32, 263-266.	0.4	2
86	La albuminuria y la enfermedad polivascular mejoran la capacidad predictiva de los modelos multivariados después de un evento cardiovascular agudo. Cohorte AIRVAG. Revista Clínica Española, 2022, 222, 138-151.	0.2	2
87	Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study. Journal of Clinical Medicine, 2021, 10, 1379.	1.0	2
88	IMMUNOSUPPRESSIVE EFFECTS OF LEFLUNOMIDE IN EXPERIMENTAL CHRONIC VASCULAR REJECTION. Transplantation, 1995, 60, 887-890.	0.5	2
89	Isoprenoids, Ras and Proliferative Glomerular Disease. , 1997, 120, 219-227.		1
90	Letter by Gujarrro Regarding Article, "Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis". Stroke, 2018, 49, e169.	1.0	1

#	ARTICLE	IF	CITATIONS
91	2.P.72 Atorvastatin inhibition of NF- κ B activation in vascular smooth muscle cells is mediated by protein isoprenylation blockade. <i>Atherosclerosis</i> , 1997, 134, 131.	0.4	0
92	Standards and iteroperability in E-government initiatives. , 0, , .		0
93	P202 PERSISTENT LIPID ABNORMALITIES IN STATIN TREATED PATIENTS IN SPAIN. THE DYSLIPIDEMIA INTERNATIONAL SURVEY STUDY (DYSIS-SPAIN). <i>Atherosclerosis Supplements</i> , 2010, 11, 58-59.	1.2	0
94	MS214 ASSOCIATION BETWEEN LOW HDL-C AND FAMILY HISTORY OF PREMATURE CORONARY HEART DISEASE IN SPANISH STATIN-TREATED PATIENTS. THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS-SPAIN). <i>Atherosclerosis Supplements</i> , 2010, 11, 153.	1.2	0
95	820 MICROALBUMINURIA ANKLE-BRACHIAL INDEX (ABI) AND SYSTOLIC HYPERTENSION ARE THE STRONGEST PREDICTORS OF RECURRENT ATHEROSCLEROTIC EVENTS. THE AIRVAG COHORT EXTENDED FOLLOW-UP. <i>Atherosclerosis Supplements</i> , 2011, 12, 172.	1.2	0
96	Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 67-69.	0.1	0
97	Epidemiological Burden and Management of Hypercholesterolemia in High Cardiovascular Risk Patients in Spain: a Comprehensive Picture from a Systematic Review of the Literature. <i>Value in Health</i> , 2015, 18, A381.	0.1	0
98	Direct Costs And Healthcare Resource Use Associated With Patients With Hypercholesterolaemia And Established Cardiovascular Disease In Spain. <i>Value in Health</i> , 2017, 20, A619.	0.1	0
99	Efficacy of PCSK9 inhibitors in the clinical practice. First year experience. <i>Atherosclerosis</i> , 2018, 275, e233.	0.4	0
100	Uso de la polipÃdora cardiovascular 40 mg en prevenciÃ³n cardiovascular secundaria. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis</i> , 2018, 30, 240-247.	0.4	0
101	Predictive performance of framingham, regicor, score, reach, b-timi and smart scales in secondary cardiovascular prevention. The airvag cohort. <i>Atherosclerosis</i> , 2019, 287, e84-e85.	0.4	0
102	FRI0699-HPRâ€...DEVELOPMENT OF DELPHI-BASED RECOMMENDATIONS FOR THE MANAGEMENT OF CARDIOVASCULAR COMORBIDITIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND MODERATE-TO-SEVERE PSORIASIS: STUDY PROTOCOL. , 2019, , .		0
103	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
104	GuÃas de prevenciÃ³n cardiovascular de sociedades cientÃficas y administraciones sanitarias: la necesidad de convergencia. <i>Revista Clinica Espanola</i> , 2020, 220, 294-296.	0.2	0
105	Validation of the QMon-20 oscillometric blood pressure monitor for professional office use in the general population according to the ANSI/ESH/ISO 81060â€2:2018 protocol. <i>Blood Pressure Monitoring</i> , 2021, 26, 393-395.	0.4	0
106	External validation of the European and American equations for calculating cardiovascular risk in a Spanish working population. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2021, 221, 561-568.	0.3	0
107	EPOC y enfermedad cardiovascular: algo mÃs que una co-incidencia. <i>Revista Clinica Espanola</i> , 2020, 220, 290-291.	0.2	0
108	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition)</i> , 2022, 34, 10-18.	0.1	0